Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Diagnosis and risk stratification of acute myeloid leukemia (AML) rely on the detection of diverse genetic aberrations using multiple standard-of-care (SoC) assays. With the increasing number of clinically relevant alterations and limited resolution of SoC methods, whole-genome and transcriptome sequencing (WGTS) represents a promising alternative. In this multi-center study, we evaluated the technical feasibility and clinical performance of WGTS across five sites in Sweden by comparison with SoC diagnostics. A total of 235 patients (197 adults and 38 children) underwent parallel SoC testing and WGTS analysis. WGTS identified 57/58 (98%) clinically relevant gene rearrangements detected by SoC and revealed an additional 12 rearrangements, including RUNX1 :: RUNX1T1 , KMT2A and NUP98 rearrangements. For structural variants and copy-number variants, WGS showed 90% concordance with SoC, with discrepancies mainly involving subclonal events or tetraploidy. For gene mutations, WGS achieved 94% sensitivity, detecting all NPM1, CEBPA bZIP, and IDH1/2 mutations, but missing low-frequency FLT3 -ITDs. Tumor-only analysis performed comparably to paired analysis for clinically relevant variants. Diagnostic classification was highly concordant between WGTS and SoC (WHO: 94%; ICC: 93%), with improved genetic subclassification in 5–6% of cases by WGTS. ELN risk stratification was concordant in 97% with WGTS reclassifying 2% of patients. Finally, a ring trial involving seven cases demonstrated complete agreement across sites in identifying aberrations. In conclusion, WGTS is a feasible and accurate comprehensive diagnostic approach for AML in a decentralized setting, improving detection of clinically relevant aberrations. However, complementary high-sensitivity assays for FLT3- ITD remain necessary for routine clinical implementation. Key points Whole-genome and transcriptome sequencing (WGTS) uncovers all clinically relevant variants in AML detected by standard-of-care (SoC) assays, with the exception of FLT3 -ITDs at low allele frequency, which require sensitive targeted assays. Compared with SoC assays, WGTS improves detection of clinically relevant gene rearrangements, resulting in a 5–6% increase in genetically based AML diagnoses. Nationwide multicenter validation demonstrates that WGTS can be implemented in a decentralized setting.
Source: medRxiv
Authors: Anna Staffas, Lucia Cavelier, Kajsa Olde, Christina Orsmark-Pietras, Tatjana Pandzic, Irina Golovleva, Linda Olsson-Arvidsson, Aleksandra Krstic, Sailendra Pradhananga, Nina Hollfelder, Khurram Maqbool, Mathias Johansson, Panagiotis Baliakas, Leonie Saft, Vladimir Lazarevic, Martin Jädersten, Stefan Deneberg, Anna Robelius, Martin Höglund, Gustav Orrsjö, Jonas Abrahamsson, Cornelis Jan Pronk, Josefine Palle, Hartmut Vogt, Karin Belander Strålin, Ulrika Norén-Nyström, Lars Palmqvist, Valtteri Wirta, Gisela Barbany, Thoas Fioretos, Linda Fogelstrand, Richard Rosenquist
Institutions: Sahlgrenska University Hospital, Region Västra Götaland, University of Gothenburg, Karolinska University Hospital, Karolinska Institutet, Lund University, Skåne University Hospital, Region Skåne, Uppsala University, Uppsala University Hospital, Umeå University, Science for Life Laboratory, Linköping University, Region Östergötland
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: acute myeloid leukemia, whole genome sequencing, transcriptome sequencing, genetic diagnosis, pediatric acute myeloid leukemia, adult AML, gene rearrangement, RUNX1-RUNX1T1, MLL rearrangement, NUP98 rearrangement, structural variants, copy number variation, tetraploidy, NPM1 mutation, CEBPA mutation, IDH1/2 mutation, FLT3-ITD, risk stratification, ELN risk classification, interlaboratory comparison
Open Access status: green
OpenAlex ID: W7236442047
